Influence of different HRT regimens on mammographic density.

Autor: Junkermann H; Ruprecht-Karls-Universität Heidelberg, Universitäts-Frauenklinik, Abteilung für Gynäkologische Radiologie, Heidelberg, Germany. hansjunkermann@aol.com, von Holst T, Lang E, Rakov V
Jazyk: angličtina
Zdroj: Maturitas [Maturitas] 2005 Feb 14; Vol. 50 (2), pp. 105-10.
DOI: 10.1016/j.maturitas.2004.04.008
Abstrakt: Objectives: A prospective, randomized, open-label study was conducted to evaluate effects on mammographic density in postmenopausal and late perimenopausal women receiving continuous combined or sequential combined hormone replacement therapy (HRT).
Methods: The subjects were randomized to treatment with low-dose continuous combined HRT containing 1 mg 17beta-estradiol plus 0.5 mg norethisterone acetate (Activelle) or a sequential combined HRT regimen consisting of 0.625 mg conjugated equine estrogens for 28 days plus 5 mg medrogestone for 14 days (Presomen). Mammograms were obtained at baseline and after 9 cycles (each 28 days) of treatment.
Results: The majority of women (approximately two-thirds in each treatment group) had no changes in mammographic breast density between baseline and the final study visit. There were no marked differences between treatment groups. Approximately 20% of women in both groups had a slight increase in mammographic density. Only 10-14% of women in both groups had a pronounced increase in mammographic density. The analyses of the degree of change showed no remarkable differences between treatments.
Conclusion: These results indicate that the increase in mammographic density with a low-dose continuous combined HRT regimen is no greater than that with a sequential combined HRT regimen. The type of progestogen does not have an impact on the extent of mammographic density changes.
Databáze: MEDLINE
Externí odkaz: